title: Antitumor effect of radioactive cisplatin (191Pt) on nude mice.
abstract: OBJECTIVE
  To investigate the effect of (191)Pt-cisplatin in vivo in terms of the antitumor effect and general toxicity on tumor-bearing nude mice.
  
  
  METHODS
  Tumor-bearing (human squamous cell carcinoma, AB) nude mice were divided into four groups and given, i.p., physiological saline (controls), cisplatin, (191)Pt-cisplatin (80 MBq/mg), or (191)Pt-cisplatin (160 MBq/mg), respectively. Mortality and weight were used as parameters for monitoring general toxic effect, while specific growth delay (SGD) and the area under the logarithm of the relative tumor size curve (AUC-log[RTS]) were used to evaluate the antitumor effect of the treatments.
  
  
  RESULTS
  Both SGD and AUC-log(RTS) values showed that (191)Pt-cisplatin was significantly (P < 0.05) more effective in retarding tumor growth than nonradioactive cisplatin. No differences in mortality between the different groups could be observed and no significant differences in weight change between the mice treated with cisplatin or (191)Pt-cisplatin could be seen.
  
  
  CONCLUSIONS
  (191)Pt-cisplatin is a more effective drug than nonradioactive cisplatin in retarding tumor growth on nude mice without adding systemic toxic effects. We believe that radioactive cisplatin may prove to be an alternative to conventional cisplatin; however, the possible toxic effects on organs at risk have to be thoroughly investigated.
authors.affiliation: Department of Radiation Physics, Malmö University Hospital, 205 02 Malmö, Sweden. johan.areberg@rfa.mas.lu.se
authors.forename: J
authors.initials: J
authors.lastname: Areberg
authors.forename: J
authors.initials: J
authors.lastname: Wennerberg
authors.forename: A
authors.initials: A
authors.lastname: Johnsson
authors.forename: K
authors.initials: K
authors.lastname: Norrgren
authors.forename: S
authors.initials: S
authors.lastname: Mattsson
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects / Q000528:radiation effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000532:radiotherapy*; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000379:methods; D004338:Drug Combinations; D004354:Drug Screening Assays, Antitumor; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D010984:Platinum / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D011868:Radioisotopes / Q000627:therapeutic use*; D014183:Transplantation, Heterologous
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D011838:Radiation-Sensitizing Agents; D011868:Radioisotopes; D010984:Platinum; D002945:Cisplatin